en.Wedoany.com Reported - Australian mining magnate Gina Rinehart has invested $50 million in California-based Lumitron Technologies to commercialize high-resolution imaging technology that can serve both ore processing and cancer detection. The funding will advance Lumitron's HyperView ultra-high-energy electron beam technology, which is said to achieve resolution up to 1,000 times greater than traditional X-ray systems.
Lumitron's imaging technology is applicable in both medical and industrial fields, and in mining, it can be used to identify mineral compositions, detect contaminants, and assist operators in selectively processing higher-grade ore. Rinehart stated that the technology enables mining operators to selectively process higher-value ore, thereby improving recovery rates and potentially reducing energy consumption and overall processing costs. Lumitron said the investment could double to $100 million later this year, and Hancock Prospecting will also receive a board seat. The deal deepens Rinehart's support for critical minerals technology while reflecting her long-standing commitment to breast cancer initiatives, a cause stemming from the death of her mother, Hope Rinehart, from the disease.
Earlier this month, Hancock Prospecting acquired a $1 billion stake in Elon Musk's SpaceX following its record-breaking initial public offering. Rinehart also directly holds approximately $6.6 million worth of Tesla shares and recently increased Hancock's investment in Arafura Rare Earths (ASX: ARU). Her portfolio already includes major positions in rare earth producers such as MP Materials (NYSE: MP), Lynas Rare Earths (ASX: LYC), and Brazil Rare Earths (ASX: BRE), underscoring Hancock's strategy of expanding from iron ore into critical minerals and related technologies. As executive chairman of Hancock Iron Ore, formed through last year's merger of Roy Hill and Atlas Iron, Rinehart has introduced pink dump trucks, mining equipment, and personal protective equipment into operations to raise awareness and funds for breast cancer initiatives.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
